Rituximab in Primary Lymphocyte Predominant Hodgkin´s Disease(RIPL)

NCT00346684 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
OTHER
Sponsor class

Conditions

Interventions

Sponsor

University of Cologne